Agreement includes Potelligent technology system.

Lonza and Kyowa Hakko Kogyo signed an agreement today whereby Lonza will license to Kyowa Hakko and its U.S. subsidiary, BioWa (Kyowa Hakko Group), its GS Gene Expression System™ (GS: glutamine synthetase). Prior to this agreement BioWa and Lonza entered into a strategic research collaboration agreement combining Kyowa Hakko’s Potelligent® technology with Lonza’s GS Gene Expression System.

This worldwide, nonexclusive umbrella research and license agreement enables Kyowa Hakko Group to use Lonza’s GS-System and the Potelligent technology as a platform for the production of antibodies and recombinant proteins being developed by Kyowa Hakko Group.


Previous articleDompé Expresses Interest in Dyax’ Angioedema Candidate
Next articleViroPharma to Purchase Lev for $442.9M